Sugi Predict

Sugi Predict / Compounds / SCHEMBL63633

SCHEMBL63633

SCHEMBL63633

CC(C)(C)OC(=O)N1CCN(c2ccc(C(=O)O)cc2)CC1

nearest known ligand 0.65

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 4/20 0.65
▸ LMNA P02545 2/20 0.65
▸ ALDH1A1 P00352 2/20 0.65
▸ GPR119 Q8TDV5 8/20 0.62
▸ KMT2A Q03164 5/20 0.60
▸ SMN1; SMN2 Q16637 4/20 0.60
▸ MEN1 O00255 4/20 0.60
▸ CYP2C19 P33261 1/20 0.60
▸ HTT P42858 1/20 0.59
▸ NPSR1 Q6W5P4 1/20 0.59
▸ NAMPT P43490 1/20 0.56
▸ ESRRB O95718 1/20 0.55
▸ ESR1 P03372 1/20 0.55
▸ ESRRA P11474 1/20 0.55
▸ ESRRG P62508 1/20 0.55
▸ TSHR P16473 1/20 0.53
▸ USP2 O75604 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4038648 0.99 MAPT (0.64) MAPTLMNAALDH1A1GPR119KMT2A
SCHEMBL5573222 0.91 MAPT (0.76) MAPTLMNAALDH1A1GPR119KMT2A
SCHEMBL24891887 0.89 MAPT (0.64) MAPTLMNAALDH1A1GPR119KMT2A
SCHEMBL1481563 0.88 GPR119 (0.78) MAPTLMNAALDH1A1GPR119KMT2A
SCHEMBL2945397 0.88 GPR119 (0.81) MAPTLMNAALDH1A1GPR119KMT2A
SCHEMBL8354642 0.87 GPR119 (0.62) MAPTLMNAALDH1A1GPR119KMT2A
SCHEMBL8348627 0.87 GPR119 (0.62) MAPTLMNAALDH1A1GPR119KMT2A
SCHEMBL13218466 0.87 GPR119 (0.79) MAPTLMNAALDH1A1GPR119KMT2A
SCHEMBL2453801 0.87 MAPT (0.64) MAPTLMNAALDH1A1GPR119KMT2A
SCHEMBL26054723 0.87 MAPT (0.64) MAPTLMNAALDH1A1GPR119KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 303 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4746882-A1 INHIBITORS OF SMNDC1 AND THEIR THERAPEUTIC USE CeMM - Forschungszentrum für Molekulare Medizin GmbH (AT) 2026-05-27 — — EP disclosed
US-20260092057-A1 BCL-XL/BCL-2 DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS INC (US) 2026-04-02 — — US disclosed
US-20260053796-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR ARVINAS OPERATIONS INC (US) 2026-02-26 — — US disclosed
US-20260014147-A1 STAT6 DEGRADERS GILEAD SCIENCES INC (US) 2026-01-15 — — US disclosed
US-20260001893-A1 SMALL MOLECULE MODULATORS OF STAT6 GILEAD SCIENCES INC (US) 2026-01-01 — — US disclosed
US-20250340551-A1 SMALL MOLECULE MODULATORS OF STAT6 GILEAD SCIENCES INC (US) 2025-11-06 — — US disclosed
US-20250340552-A1 COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISORDERS HOTSPOT THERAPEUTICS INC (US) 2025-11-06 — — US disclosed
US-20250325677-A1 STAT6 DEGRADERS GILEAD SCIENCES INC (US) 2025-10-23 — — US disclosed
US-20250320205-A1 STAT6 DEGRADERS GILEAD SCIENCES INC (US) 2025-10-16 — — US disclosed
US-20250320206-A1 STAT6 DEGRADERS GILEAD SCIENCES INC (US) 2025-10-16 — — US disclosed
US-5854245-A Fibrinogen receptor antagonists MERCK & CO., INC. (US) 1998-12-29 — — US disclosed
EP-0885205-A1 FIBRINOGEN RECEPTOR ANTAGONISTS Merck & Co., Inc. (US) 1998-12-23 — — EP disclosed
WO-1998054164-A1 SULFONAMIDE DERIVATIVES, THEIR PRODUCTION AND USE TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1998-12-03 — — WO disclosed
WO-1998000144-A1 FIBRINOGEN RECEPTOR ANTAGONIST PRODRUGS MERCK & CO., INC. (US) 1998-01-08 — — WO disclosed
WO-1998000401-A1 FIBRINOGEN RECEPTOR ANTAGONIST PRODRUGS MERCK & CO., INC. (US) 1998-01-08 — — WO disclosed
WO-1997031910-A1 FIBRINOGEN RECEPTOR ANTAGONISTS MERCK & CO., INC. (US) 1997-09-04 — — WO disclosed
US-5648368-A ANTICOAGULANTS MERCK & CO., INC. (US) 1997-07-15 — — US disclosed
EP-0673247-A4 FIBRINOGEN RECEPTOR ANTAGONISTS. MERCK & CO INC (US) 1996-05-01 — — EP disclosed
EP-0673247-A1 FIBRINOGEN RECEPTOR ANTAGONISTS MERCK & CO. INC. (US) 1995-09-27 — — EP disclosed
WO-1994012181-A1 FIBRINOGEN RECEPTOR ANTAGONISTS MERCK & CO., INC. (US) 1994-06-09 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250340552-A1 COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISORDERS CYP27A1, PNLIP, GOT2 MAPT 1007/4885LMNA 804/4885ALDH1A1 461/4885
US-20260053796-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR AR, NR5A1, KLK3 MAPT 4164/4885LMNA 1536/4885ALDH1A1 1033/4885
US-20250325677-A1 STAT6 DEGRADERS STAT6, STAT5B, STAT1 MAPT 1017/4885LMNA 2978/4885ALDH1A1 959/4885
US-20250340551-A1 SMALL MOLECULE MODULATORS OF STAT6 STAT6, STAT1, STAT5B MAPT 1682/4885LMNA 3808/4885ALDH1A1 2050/4885
US-20260092057-A1 BCL-XL/BCL-2 DEGRADERS AND USES THEREOF BCL2L2, BCL2A1, BCL2L1 MAPT 4734/4885LMNA 3498/4885ALDH1A1 1304/4885
US-20260001893-A1 SMALL MOLECULE MODULATORS OF STAT6 STAT6, NCOR1, NCOR2 MAPT 4503/4885LMNA 3423/4885ALDH1A1 3636/4885
US-20250320205-A1 STAT6 DEGRADERS STAT6, STAT1, STAT5B MAPT 1034/4885LMNA 2666/4885ALDH1A1 1225/4885
US-20260014147-A1 STAT6 DEGRADERS STAT6, NCOR1, CBR1 MAPT 4225/4885LMNA 1900/4885ALDH1A1 1790/4885
US-20250320206-A1 STAT6 DEGRADERS STAT6, STAT5B, STAT1 MAPT 1017/4885LMNA 2978/4885ALDH1A1 959/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.